50,000/μL in average adult Fresh-frozen plasma (FFP) Bleeding associated with abnormal coagulation panel Factor deficiency replacement Reversal of vitamin K antagonist Massive transfusion requirement 10–20 mL/kg/dose (∼200–250 mL/unit) Cryoprecipitate (Cryo) Bleeding associated 1–2 units for every 10 with deficiency of kg of body weight fibrinogen, FVIII, FXIII, or VWF • Contains all plasma-clotting factors, but with variable concentrations • Contains fibrinogen, FVIII, FXIII, and VWF Recombinant Factor VIII products: factor products treatment or prophylaxis of FVIII deficiency Factor IX products: treatment or prophylaxis of FIX deficiency Factor VII (rFVIIa): treatment or prophylaxis of FVII deficiency or treatment or prophylaxis for FVIII or FIX patients with inhibitors Factor VIII: (number • Plasma-derived of units = desired factor level [%] × weight replacement of patient [kg] × 0.5) products also available Factor IX: (number of units = desired level [%] × weight of patient [kg]) Factor VII: Replacement: 15–30 mcg/kg q4–q6hr FVIII or FIX inhibitors: 90 mcg/kg q2hr, space as clinically tolerated Antihemophilic factor/VWF complex von Willebrand disease (VWD) Dosing based on VWF:RCo units/kg Prothrombin complex concentrates Bleeding with Consult hematologist, deficiency of FII, dose for factor FVII, FIX, FX, or replacement based familial vitamin K on specific factor deficiency or • Contraindicated in DIC, HIT, or known hypersensitivity